Bill Text: FL S0186 | 2024 | Regular Session | Enrolled
Bill Title: Progressive Supranuclear Palsy and Other Neurodegenerative Diseases Policy Committee
Spectrum: Bipartisan Bill
Status: (Passed) 2024-05-13 - Chapter No. 2024-165 [S0186 Detail]
Download: Florida-2024-S0186-Enrolled.html
ENROLLED 2024 Legislature CS for SB 186 2024186er 1 2 An act relating to a progressive supranuclear palsy 3 and other neurodegenerative diseases policy committee; 4 providing a short title; requiring the State Surgeon 5 General to establish a progressive supranuclear palsy 6 and other neurodegenerative diseases policy committee; 7 requiring the Department of Health to provide staff 8 and administrative support to the committee; providing 9 for duties, membership, and meetings of the committee; 10 requiring the State Surgeon General to submit a 11 progress report and a final report by a specified date 12 to the Governor and the Legislature; requiring the 13 reports to be made available on the department’s 14 website; providing for the expiration of the 15 committee; providing an effective date. 16 17 Be It Enacted by the Legislature of the State of Florida: 18 19 Section 1. This act may be cited as the “Justo R. Cortes 20 Progressive Supranuclear Palsy Act.” 21 Section 2. Progressive supranuclear palsy and other 22 neurodegenerative diseases policy committee.— 23 (1) The State Surgeon General shall establish a progressive 24 supranuclear palsy and other neurodegenerative diseases policy 25 committee, a committee as defined in s. 20.03, Florida Statutes. 26 The Department of Health shall provide staff and administrative 27 support to the committee for purposes of carrying out its duties 28 and responsibilities. 29 (2) The committee shall do all of the following: 30 (a) Identify the aggregate number of people in the state 31 diagnosed with progressive supranuclear palsy or other 32 neurodegenerative diseases annually. 33 (b) Identify how data is collected regarding diagnoses of 34 progressive supranuclear palsy or other neurodegenerative 35 diseases and adverse health outcomes associated with such 36 conditions. 37 (c) Identify how progressive supranuclear palsy and other 38 neurodegenerative diseases impact the lives of people in the 39 state. 40 (d) Identify the standard of care for the surveillance, 41 detection, and treatment of progressive supranuclear palsy and 42 other neurodegenerative diseases. 43 (e) Identify emerging treatments, therapies, and research 44 relating to progressive supranuclear palsy and other 45 neurodegenerative diseases. 46 (f) Develop a risk surveillance system to help health care 47 providers identify patients who may be at a higher risk of 48 developing progressive supranuclear palsy and other 49 neurodegenerative diseases. 50 (g) Develop policy recommendations to help improve patient 51 awareness of progressive supranuclear palsy and other 52 neurodegenerative diseases. 53 (h) Develop policy recommendations to help improve 54 surveillance and detection of patients who may be at a higher 55 risk of being diagnosed with progressive supranuclear palsy and 56 other neurodegenerative diseases in licensed health care 57 facilities, including hospitals, nursing homes, assisted living 58 facilities, residential treatment facilities, and ambulatory 59 surgical centers. 60 (i) Develop policy recommendations relating to guidelines 61 that affect the standard of care for patients with progressive 62 supranuclear palsy or other neurodegenerative diseases. 63 (j) Develop policy recommendations relating to providing 64 patients and their families with written notice of increased 65 risks of being diagnosed with progressive supranuclear palsy and 66 other neurodegenerative diseases. 67 (3) The committee shall be composed of 20 members, 68 including the State Surgeon General. Members of the committee 69 must be appointed by September 1, 2024. 70 (a) The State Surgeon General shall appoint health care 71 providers, family members or caretakers of patients who have 72 been diagnosed with progressive supranuclear palsy and other 73 neurodegenerative diseases, advocates, and other interested 74 parties and associations. 75 (b) The President of the Senate and the Speaker of the 76 House of Representatives shall each appoint two members to the 77 committee. 78 (c) Members of the committee shall serve without 79 compensation and for the entirety of the committee’s existence. 80 (d) The State Surgeon General shall appoint the chair of 81 the committee. 82 (e) The chair of the committee may create subcommittees to 83 help conduct research, schedule speakers on important subjects, 84 and draft reports and policy recommendations. 85 (f) Meetings of the committee shall be held through 86 teleconference or other electronic means. The committee shall 87 meet for its initial meeting by October 1, 2024. Thereafter, the 88 committee may meet upon the call of the chair or upon the 89 request of a majority of its members. Notices for any scheduled 90 meetings of the committee must be published in advance on the 91 department’s website. 92 (4)(a) The State Surgeon General shall submit a progress 93 report detailing committee activities, as well as his or her 94 findings and recommendations, to the Governor, the President of 95 the Senate, and the Speaker of the House of Representatives by 96 January 4, 2025. The report must be made available on the 97 department’s website. 98 (b) The State Surgeon General shall submit a final report 99 detailing committee activities, as well as his or her findings 100 and recommendations, to the Governor, the President of the 101 Senate, and the Speaker of the House of Representatives by 102 January 4, 2026. The report must be made available on the 103 department’s website. 104 (5) The committee shall sunset July 1, 2026, and this 105 section is repealed on that date. 106 Section 3. This act shall take effect July 1, 2024.